Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Breast Cancer Research : BCR|March 16, 2012
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancerIsabel Pinhel, Margaret Hills, Suzanne Drury, et al.
Trials|June 15, 2021
Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial designIndrani S Bhattacharya, Joanne S Haviland, Lesley Turner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trialIndrani S Bhattacharya, Joanne S Haviland, Carola Perotti, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 6, 2021
When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer ManagementSamilia Obeng-Gyasi, Charlotte E Coles, Jade Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized TrialRosalind A Eeles, James P Morden, Martin Gore, et al.
The New England Journal of Medicine|February 20, 2004
Excision margins in high-risk malignant melanomaJ Meirion Thomas, Julia Newton-Bishop, Roger A'Hern, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2025
Baseline characteristics predicting lower return rates of missing patient-reported quality of life data over 5 years: evidence from the IMPORT HIGH and IMPORT LOW breast cancer radiotherapy trialsSzeyi Ng, Anna M Kirby, Lucy S Kilburn, et al.
Breast Cancer Research and Treatment|August 24, 2010
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane StudyRobert E Coleman, Linda M Banks, Samia I Girgis, et al.
Breast Cancer Research and Treatment|January 26, 2019
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIESZsolt Szijgyarto, Koen D Flach, Mark Opdam, et al.
JCO Precision Oncology|September 11, 2020
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor TreatmentEugene F Schuster, Pascal Gellert, Corrinne V Segal, et al.
Pageof 10